The investigation concerns whether The Medicine Companies violated federal securities laws. On February 10, 2014, the Food and Drug Administration ("FDA") published a report regarding Medicines’ clinical trial called CHAMPION of one of Medicines drug candidates named Cangrelor. Cangrelor is designed to prevent blood clots during heart artery-clearing angioplasty and stenting procedures. The FDA report found Cangrelor did not show the request efficacy as it was not superior to an already approved drug. Perhaps most concerning though, The FDA opined that the CHAMPION clinical trials sponsored by Medicines were unethically and inappropriately administered. The FDA alleged that during head to head comparisons between Cangrelor, on the one hand, and a competing drug, on the other hand, during the CHAMPION clinical trials, the clinical trial delayed the administration of the competing drug in patients and lowered the dosage of the competing drug. The FDA report stated that, "because the CHAMPION trials were conducted unethically. We can refuse approval of Cangrelor based on that fact alone."